300
Views
24
CrossRef citations to date
0
Altmetric
Special Report

Narcolepsy in Parkinson’s disease

, , &
Pages 879-884 | Published online: 09 Jan 2014

References

  • Anders TF, Guilleminault C. The pathophysiology of sleep disorders in paediatrics. Part I. Sleep in infancy. Adv. Pediatr.22, 137–150 (1976).
  • Guilleminault C, Anders TF. The pathophysiology of sleep disorders in paediatrics. Part II. Sleep disorders in children. Adv. Pediatr.22, 151–174 (1976).
  • Guilleminault C, Wilson RA, Dement WC. A study on cataplexy. Arch. Neurol.31(4), 255–261 (1974).
  • Beck B, Richy S. Hypothalamic hypocretin/orexin and neuropeptide Y: divergent interaction with energy depletion and leptin. Biochem. Biophys. Res. Commun.258, 119–122 (1999).
  • Kalra SP, Dube MG, Pu S, Xu B, Horvath TL, Kalra PS. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev.20, 68–100 (1999).
  • Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu. Rev. Neurosci.24, 429–458 (2001).
  • Kilduff TS. Hypocretin/orexin: maintenance of wakefulness and a multiplicity of other roles. Sleep Med. Rev.9, 227–230 (2005).
  • Kok SW, Meinders AE, Overeem S et al. Reduction of plasma leptin levels and loss of its circadian rhythmicity in hypocretin-deficient narcoleptic humans. J. Clin. Endocrinol. Metab.87(2), 805–809 (2002).
  • Sakurai T. Physiological reviews: roles of hypocretin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. Sleep Med. Rev.9, 231–242 (2005).
  • Gulati A, Forbes A, Stegie F, Kelly L, Clough C, Chaudhuri KR. A clinical observational study of the pattern and occurrence of non-motor symptoms in Parkinson’s disease ranging from early to advanced disease. Mov. Disord.19, S406 (2004).
  • Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based prospective study. J. Am. Geriatr.48, 938–942 (2000).
  • Findley L, Aujila M, Bain PG et al. Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov. Disord.18, 1139–1145 (2003).
  • Chaudhuri KR, Healy D, Schapira AHV. The non motor symptoms of Parkinson’s disease. Diagnosis and management. Lancet Neurol.5, 235–245 (2006).
  • Braak H, Del Tredici K, Rüb U, de Vos R, Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging24(2), 197–211 (2003).
  • Baumann CR, Bassetti CL. Hypocretins (orexins) and sleep-wake disorders. Lancet10, 673–682 (2005).
  • Aldrich MS. Diagnostic aspects of narcolepsy. Neurology50, S2–S7 (1998).
  • Didato G, Nobili L. Treatment of narcolepsy. Expert Rev. Neurother.9(6), 897–910 (2009).
  • Britton TC. Chaudhuri KR. REM sleep behavior disorder and the risk of developing Parkinson disease or dementia. Neurology1472(15), 1294–1295 (2009).
  • Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med. Rev.9, 185–200 (2005).
  • Chaudhuri KR. Nocturnal symptom complex in PD and its management. Neurology61(Suppl. 3), S17–S23 (2003).
  • Garcia-Borreguero D, Larosa O, Bravo M. Parkinson’s disease and sleep. Sleep Med. Rev.7, 115–129 (2003).
  • Baumann CR, Bassetti CL. Hypocretins (orexins): clinical impact of the discovery of neurotransmitter. Sleep Med. Rev.9, 253–268 (2005).
  • Andreu N, Chale JJ, Senard JM, Thalamas C, Montastruc JI, Rascol O. l-DOPA induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin. Neuropharacol.22, 15–23 (1999).
  • Frucht SJ, Rogers JD, Greene PE, Gordon MD, Fahn S. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology52, 1908–1910 (1999).
  • Ferreira JJ, Galitzky M, Montastruc JL, Rascol O. Sleep attacks in Parkinson’s disease. Lancet355, 1333–1334 (2000).
  • R v Brian Thomas [2009] (Unreported, November 2009); R v Lowe [2005] (Unreported, March 2005, CC Manchester); R v Parks [1992] 2 S.C.R. 871.
  • Gagnon JF, Bedard MA, Fantini ML et al. REM sleep behaviour disorder and REM sleep without atonia in Parkinson’s disease. Neurology59, 585–589 (2002).
  • Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology46(2), 388–393 (1996).
  • Arnulf I, Bonnet AM, Damier P et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology55, 281–288 (2000).
  • Onofrj M, Luciano AL, Iacono D et al. HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson’s disease. Mov. Disord.18, 337–340 (2003).
  • Benbir G, Ozekmekci S, Cinar M, Beskardes F, Apaydin H, Erginoz E. Features associated with the development of hallucinations in Parkinson’s disease. Acta Neurol. Scand.114, 239–243 (2006).
  • Sakurai T, Moriguchi T, Furuya K et al. Structure and function of human prepro-hypocretin gene. J. Biol. Chem.274, 17771–17776 (1999).
  • Gautvik KM, de Lecea L, Gautvik VT et al. Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proc. Natl Acad. Sci. USA93(16), 8733–8738 (1996).
  • de Lecea L, Kilduff TS, Peyron C et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA95, 322–327 (1998).
  • Peyron C, Tighe DK, Van den Pol AN et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci.18, 9996–10015 (1998).
  • Lin L, Faraco J, Li R et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell698(3), 365–376 (1999).
  • Mitler MM, Harsh J, Hirshkowitz M et al. Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Med.11(3), 231–243 (2000).
  • Chemelli RM, Willie JT, Sinton CM et al. Narcolepsy in hypocretin knockout mice: molecular genetics of sleep regulation. Cell98, 437–451 (1999).
  • Espana RA, Baldo BA, Kelley AE, Berridge CW. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience106, 699–715 (2001).
  • Hagan JJ, Leslie RA, Patel S et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl Acad. Sci. USA96, 10911–10916 (1999).
  • Piper DC, Upton N, Smith MI, Hunter AJ. The novel brain neuropeptide, orexin-A. modulates the sleep–wake cycle of rats. Eur. J. Neurosci.12, 726–730 (2000).
  • Li Y, Gao XB, Sakurai T. Hypocretin/orexin excites hypocretin neurons via a local glutamate neuron – a potential mechanism for orchestrating the hypothalamic arousal system. Neuron36, 1169–1181 (2002).
  • Yamanaka A, Muraki Y, Tsujino N et al. Regulation of hypocretin neurons by the monoaminergic and cholinergic systems. Biochem. Biophys. Res. Commun.303, 120–129 (2003).
  • Yang B, Sampson K, Ferguson AV. Excitatory effects of hypocretin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C. J. Neurosci.23, 6215–6222 (2003).
  • Mieda M, Wille JT, Hara J et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl Acad. Sci. USA101, 4649–4954 (2004).
  • Moore RY, Silver R. Suprachiasmatic nucleus organization. Chronobiol. Int.15, 475–487 (1998).
  • Saper C, Chou TC, Scammell TE. The sleep switch: hypothalamic control of sleep and wakefulness. Trends Neurosci.24, 726–731 (2001).
  • Korten JJ, Meulstee J. Olfactory disturbances in parkinsonism. Clin. Neurol. Neurosurg.82(2), 113–118 (1980).
  • Singh S, Schwankhaus J. Olfactory disturbance in Parkinson disease. Arch. Neurol.66(6), 805 (2009).
  • Abbott RD, Ross GW, White LR et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology65, 1442–1446 (2005).
  • Iranzo A, Molinuevo JL, Santamaria J et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol.5, 572–577 (2006).
  • Nishino S, Ripley B, Overeem S et al. Hypocretin deficiency in human narcolepsy. Lancet355, 39–40 (2000).
  • Mignot E, Lammers GJ, Ripley B et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch. Neurol.59(10), 1553–1562 (2002).
  • Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy, and hypersomnia, and their implications in the hypothalamic hypocretin/hypocretin system. Sleep Med. Rev.9, 269–310 (2005).
  • Thannickal TC, Moore RY, Nienhuis R et al. Reduced number of hypocretin peptides in human narcolepsy. Neuron27, 469–474 (2000).
  • Fronczek R, Baumann CR, Lammers GJ, Bassetti CL, Overeem S. Hypocretin/orexin disturbances in neurological disorders. Sleep Med. Rev.13, 9–22 (2009).
  • Fronczek R, Overeem S, Lee SYY et al. Hypocretin (orexin) loss in Parkinson’s disease. Brain130, 1577–1585 (2007).
  • Gerashchenko D, Murillo-Rodriguez E, Lin L et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp. Neurol.184, 1010–1016 (2003).
  • Butkov N, Lee-Chiong TL (Eds). Fundamentals of Sleep Technology. Lipincott Williams & Wilkins, PA, USA 164 (2007).
  • Baumann CR, Dauvilliers Y, Mignot E, Bassetti CL. Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness. Eur. Neurol.52(2), 73–76 (2004).
  • Ripley B, Overeem S, Fujiki N et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology57, 2253–2258 (2001).
  • Overeem S, van Hilten JJ, Ripley B, Mignot E, Nishino S, Lammers GJ. Normal hypocretin-1 levels in Parkinson’s disease patients with excessive daytime sleepiness. Neurology58, 498–499 (2002).
  • Drouot X, Moutereau S, Nguyen JP et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology2661(4), 540–543 (2003).
  • Yasui K, Inoue Y, Kanbayashi T, Nomura T, Kusumi M, Nakashima K. CSF orexin levels of Parkinson’s disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J. Neurosci.250, 120–123 (2006).
  • Maeda T, Nagata K, Kondo H, Kanbayashi T. Parkinson’s disease comorbid with narcolepsy presenting low CSF hypocretin/orexin level. Sleep Med.8, 662 (2006).
  • Compta Y, Santamaria J, Ratti L et al. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson’s disease dementia. Brain132(Pt 12), 3308–3317 (2009).
  • Asai H, Hirano M, Furiya Y et al. Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson’s disease. Clin. Neurol. Neurosurg.111, 341–344 (2009).
  • Asai H, Hirano M, Furiya Y et al. Cerbrospinal fluid orexin levels and sleep attacks in four patients with Parkinson’s disease. Clin. Neurol. Neurosurg.11, 341–344 (2009).
  • Thannickal TC, Lai Y-Y, Siegel J. Hypocretin and melanin concentrating hormone loss and the symptoms of Parkinson’s disease. Brain130, 1586–1595 (2007).
  • Chaudhuri KR. Logishetty K. Dopamine receptor agonists and sleep disturbances in Parkinson’s disease. Parkinsonism Relat. Disord.15S, S1–S4 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.